米非司酮在子宫内膜异位症患者腹腔镜手术中的应用研究

Application of Mifepristone in Laparoscopic Surgery in Patients with Endometriosis

目的观察促黄体激素释放激素类似物与米非司酮联合治疗,子宫内膜异位症腹腔镜手术患者的血清性激素水平的变化情况。方法选取我院2019年5月~2020年10月收治的116例子宫内膜异位症患者,根据住院尾号奇、偶数分为两组,各58例,对照组给予促性腺激素释放激素治疗,观察组促性腺激素释放激素联合米非司酮,比较治疗前、结束时血清相关指标[促卵泡激素(FSH)、雌二醇(E2)、睾酮(T)、黄体生成素(LH)、血管内皮生长因子(VEGF)水平,基质金属蛋白酶-9(MMP-9)、脂氧素A4(LXA4)]及不良反应。结果治疗结束时,观察组FSH、LH、E2、T低于对照组,差异有统计学意义(P<0.05);观察组VEGF、MMP-9水平低于对照组,LXA4高于对照组,差异有统计学意义(P<0.05);两组患者治疗期间失眠、潮热、阴道干涩等不良反应总发生率对比,差异无统计学意义(P>0.05)。结论子宫内膜异位症患者腹腔镜术后给予促黄体激素释放激素类似物联合米非司酮治疗,可改善机体血清性激素水平,缓解炎症状态,利于子宫内膜异位症腹腔镜手术患者恢复。

Objective To observe the changes of serum sex hormone levels in patients undergoing laparoscopic surgery for endometriosis during combined treatment of luteinizing hormone releasing hormone analogues and mifepristone.Methods A total of 116 patients with endometriosis admitted to our hospital from May 2019 to October 2020 were selected and divided into two groups according to the odd and even numbers of hospitalized tail numbers,with 58 cases in each group.The control group was given gonadotropin-releasing hormone therapy,and the observation group was given gonadotropin-releasing hormone combined with mifepristone.Compare serum related indicators before and at the end of treatment[Follicle Stimulating Hormone(FSH),Estradiol(E2),Testosterone(T),Luteinizing Hormone(LH),Vascular Endothelial Growth Factor(VEGF)Levels,Matrix Metalloproteinase-9(MMP-9),lipoxin A4(LXA4)]and adverse reactions.Results At the end of the treatment,the FSH,LH,E2 and T of the observation group were lower than those of the control group,the difference was statistically significant(P<0.05);The levels of VEGF and MMP-9 in the observation group were lower than those in the control group,and LXA4 was higher than the control group,the difference was statistically significant(P<0.05);There was no statistically significant difference in the total incidence of adverse reactions such as insomnia,hot flashes,and vaginal dryness between the two groups of patients during treatment(P>0.05).Conclusion The treatment of luteinizing hormone releasing hormone analogue combined with mifepristone in patients with endometriosis after laparoscopic surgery can improve the body's serum sex hormone levels,relieve inflammation,and benefit the recovery of endometriosis patients undergoing laparoscopic surgery.